Tenax Therapeutics (TENX) Gains from Sales and Divestitures (2016 - 2017)
Historic Gains from Sales and Divestitures for Tenax Therapeutics (TENX) over the last 5 years, with Q3 2017 value amounting to $116525.0.
- Tenax Therapeutics' Gains from Sales and Divestitures rose 4845208.33% to $116525.0 in Q3 2017 from the same period last year, while for Sep 2017 it was $116525.0, marking a year-over-year increase of 4845208.33%. This contributed to the annual value of $16.0 for FY2016, which is N/A changed from last year.
- As of Q3 2017, Tenax Therapeutics' Gains from Sales and Divestitures stood at $116525.0, which was up 4845208.33% from $116525.0 recorded in Q2 2017.
- Tenax Therapeutics' Gains from Sales and Divestitures' 5-year high stood at $116525.0 during Q2 2017, with a 5-year trough of -$17700.0 in Q3 2014.
- For the 5-year period, Tenax Therapeutics' Gains from Sales and Divestitures averaged around $33766.4, with its median value being $29796.0 (2014).
- Per our database at Business Quant, Tenax Therapeutics' Gains from Sales and Divestitures crashed by 137890.17% in 2014 and then soared by 15116363.64% in 2017.
- Over the past 5 years, Tenax Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $50062.0 in 2013, then crashed by 40.48% to $29796.0 in 2014, then crashed by 99.42% to $174.0 in 2015, then crashed by 90.8% to $16.0 in 2016, then soared by 728181.25% to $116525.0 in 2017.
- Its last three reported values are $116525.0 in Q3 2017, $116525.0 for Q2 2017, and $116473.0 during Q1 2017.